Skip to content

Study · Randomized controlled trial · 1989

5 results

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.

Peeling WB

Urology1 May 1989Cited by 113 (Europe PMC)

PMID2523611 (opens in a new tab)DOI10.1016/0090-4295(89)90106-4 (opens in a new tab)PepBankPUB-02523611
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, goserelin and orchiectomy did not differ significantly in subjective, objective or endocrine responses, clinical effects, side effects, treatment-failure time, death time or survival.

    In plain wordsIn advanced prostate cancer, goserelin and orchiectomy did not differ significantly across reported response, clinical, safety and survival outcomes.

    Peptide
    Goserelin
    Outcome
    No significant changeClinical, endocrine and safety outcomes versus orchiectomy
    Study

    n: not reported in source

    Comparator
    Orchiectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg/28 d · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the Zoladex versus orchiectomy trial, there was no significant difference between the treatment groups with regard to subjective and objective responses (British Prostate Group criteria), endocrine responses, clinical effects and side effects, time to treatment failure and death, or survival afte…
    1 context sentence
    Summary · context
    Two multicenter, open, randomized phase III clinical trials were conducted in the United Kingdom to compare the effectiveness and safety of the depot formulation of the luteinizing hormone-releasing hormone (LHRH) agonist goserelin
  2. 02HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, subjective and objective responses, response duration and survival were similar with goserelin and DES.

    In plain wordsIn advanced prostate cancer, subjective and objective responses, response duration and survival were similar with goserelin and DES.

    Peptide
    Goserelin
    Outcome
    Direction not reportedResponses, response duration and survival versus DES
    Study

    n: not reported in source

    Comparator
    Diethylstilbestrol
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg/28 d · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the Zoladex versus DES trial, subjective and objective responses (British Prostate Group and National Prostatic Cancer Project criteria), response duration and survival were similar.
    1 context sentence
    Summary · context
    Two multicenter, open, randomized phase III clinical trials were conducted in the United Kingdom to compare the effectiveness and safety of the depot formulation of the luteinizing hormone-releasing hormone (LHRH) agonist goserelin
  3. 03HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, treatment response was more rapid with goserelin than with diethylstilbestrol.

    In plain wordsIn advanced prostate cancer, response was faster with goserelin than with diethylstilbestrol.

    Peptide
    Goserelin
    Outcome
    IncreaseSpeed of response
    Study

    n: not reported in source

    Comparator
    Diethylstilbestrol
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg/28 d · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    However, there was a more rapid response to treatment in the depot Zoladex group.
    1 context sentence
    Summary · context
    Two multicenter, open, randomized phase III clinical trials were conducted in the United Kingdom to compare the effectiveness and safety of the depot formulation of the luteinizing hormone-releasing hormone (LHRH) agonist goserelin
  4. 04HumanRandomized controlled trialSafety outcome

    In advanced prostate cancer, goserelin side effects required no discontinuation, whereas 15 percent receiving DES stopped during the first three months because of side effects.

    In plain wordsIn advanced prostate cancer, side effects required no goserelin discontinuation, whereas 15 percent receiving DES stopped during the first three months.

    Peptide
    Goserelin
    Outcome
    DecreaseDiscontinuation due to side effects
    Study

    n: not reported in source

    Comparator
    Diethylstilbestrol
    Outcome group
    Adverse events · Cancer
    Studied dose
    3.6 mg/28 d · subcutaneousAs given in this study (human).

    Measurements

    Patients who stopped therapy because of side effects
    15%
    diethylstilbestrol group, first three months

    Source sentences

    Summary
    Side effects from Zoladex such as flare symptoms during the initial stages of treatment required no discontinuation of therapy; in contrast, 15 percent of patients receiving DES required cessation of therapy during the first three months because of side effects.
    1 context sentence
    Summary · context
    Two multicenter, open, randomized phase III clinical trials were conducted in the United Kingdom to compare the effectiveness and safety of the depot formulation of the luteinizing hormone-releasing hormone (LHRH) agonist goserelin
  5. 05HumanNon-randomized trialSafety outcome

    In advanced prostate cancer, goserelin caused initial flare symptoms that required no treatment discontinuation.

    In plain wordsIn advanced prostate cancer, initial flare symptoms with goserelin required no treatment discontinuation.

    Peptide
    Goserelin
    Outcome
    Direction not reportedFlare symptoms
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cancer
    Studied dose
    3.6 mg/28 d · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Side effects from Zoladex such as flare symptoms during the initial stages of treatment required no discontinuation of therapy;
    1 context sentence
    Summary · context
    Two multicenter, open, randomized phase III clinical trials were conducted in the United Kingdom to compare the effectiveness and safety of the depot formulation of the luteinizing hormone-releasing hormone (LHRH) agonist goserelin

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.